Study compares urinary albumin-to-creatinine ratio with finerenone–empagliflozin versus the single agents alone in patients with chronic kidney disease and type 2 diabetes.
Study finds a two-fold higher risk of developing nAMD in older patients with diabetes taking a GLP-1 RA compared to similar patients with diabetes not exposed to GLP1 RAs.
Incorporates new evidence with the aim to prevent end-stage kidney disease in most people with diabetes by adopting health behaviours and use of pharmacologic therapies.